CVS Health Corp (CVS) Expected to Post Quarterly Sales of $47.58 Billion

Equities research analysts predict that CVS Health Corp (NYSE:CVS) will report $47.58 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Eighteen analysts have made estimates for CVS Health’s earnings. The highest sales estimate is $48.26 billion and the lowest is $46.84 billion. CVS Health posted sales of $45.97 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 3.5%. The firm is expected to announce its next earnings report before the market opens on Thursday, February 8th.

On average, analysts expect that CVS Health will report full year sales of $47.58 billion for the current fiscal year, with estimates ranging from $183.22 billion to $184.55 billion. For the next year, analysts forecast that the business will report sales of $188.04 billion per share, with estimates ranging from $186.91 billion to $190.53 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for CVS Health.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The company had revenue of $46.18 billion for the quarter, compared to the consensus estimate of $46.17 billion. During the same quarter last year, the business posted $1.64 earnings per share. The firm’s revenue was up 3.5% compared to the same quarter last year.

CVS has been the topic of a number of research analyst reports. Leerink Swann reissued an “outperform” rating and issued a $85.00 target price (down previously from $90.00) on shares of CVS Health in a research note on Tuesday, November 7th. Oppenheimer reissued a “buy” rating and issued a $95.00 target price on shares of CVS Health in a research note on Monday, October 9th. Raymond James Financial raised CVS Health from an “outperform” rating to a “strong-buy” rating and set a $90.00 target price on the stock in a research note on Thursday, January 4th. They noted that the move was a valuation call. SunTrust Banks set a $85.00 target price on CVS Health and gave the company a “buy” rating in a research note on Thursday, October 12th. Finally, Needham & Company LLC reissued a “hold” rating on shares of CVS Health in a research note on Thursday, October 12th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $88.06.

In other news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at $1,166,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.61% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the company. Pathstone Family Office LLC grew its stake in shares of CVS Health by 341.0% in the second quarter. Pathstone Family Office LLC now owns 1,270 shares of the pharmacy operator’s stock worth $2,353,000 after purchasing an additional 982 shares during the last quarter. Wealthcare Advisory Partners LLC grew its stake in shares of CVS Health by 330.3% in the third quarter. Wealthcare Advisory Partners LLC now owns 1,291 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 991 shares during the last quarter. Fieldpoint Private Securities LLC grew its stake in shares of CVS Health by 333.3% in the second quarter. Fieldpoint Private Securities LLC now owns 1,300 shares of the pharmacy operator’s stock worth $105,000 after purchasing an additional 1,000 shares during the last quarter. Arcadia Investment Management Corp MI grew its stake in shares of CVS Health by 119.6% in the third quarter. Arcadia Investment Management Corp MI now owns 1,333 shares of the pharmacy operator’s stock worth $108,000 after purchasing an additional 726 shares during the last quarter. Finally, MPS Loria Financial Planners LLC bought a new stake in shares of CVS Health in the second quarter worth about $119,000. 81.69% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health (NYSE:CVS) opened at $76.45 on Monday. The company has a market capitalization of $77,443.23, a price-to-earnings ratio of 13.39, a P/E/G ratio of 1.28 and a beta of 0.93. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55. CVS Health has a 12 month low of $66.45 and a 12 month high of $84.00.

The business also recently disclosed a quarterly dividend, which was paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th were paid a dividend of $0.50 per share. The ex-dividend date was Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.62%. CVS Health’s dividend payout ratio (DPR) is currently 41.32%.

TRADEMARK VIOLATION NOTICE: “CVS Health Corp (CVS) Expected to Post Quarterly Sales of $47.58 Billion” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/05/cvs-health-corp-cvs-expected-to-post-quarterly-sales-of-47-58-billion.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply